Senior Vice President, Head of Finance

Andrew Prosser

An experienced finance professional, Andrew has held leadership roles in the biotech and pharma industry for over 25 years, leading, building and transforming the full range of finance and associated operations.

Most recently he led the finance function and played a key role in the funding, operations and M&A activities at Aiolos Bio (SVP Finance 2022-2024, with GSK acquisition $1.4bn in 2024); Beacon Therapeutics (interim CFO 2023-2024 with Series B $170m in 2024); and Gyroscope Therapeutics (SVP Finance 2019-2022 with Novartis acquisition $1.5bn in 2022). Prior to that he led finance in senior roles in Sanofi across Europe, as well as at Otsuka Pharmaceuticals.

Andrew is a Chartered Accountant with a degree in Mathematics from the University of Nottingham and a Masters-level Diploma in Financial Strategy from the University of Oxford.